Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Xofluza was well tolerated, and no new safety signals were identified.On Thursday, Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral that showed a reduction in the transmission of influenza viruses.
週四，羅氏控股股份有限公司（OTC：RHHBY）發佈了Xofluza（巴洛克維爾坎酯）第3期CENTERSTONE研究的積極頭條結果，這是一種抗病毒藥物，顯示了對流感病毒傳播的減少。
The study met its primary endpoint, demonstrating that a single oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus.
該研究達到了主要終點，證明Xofluza單劑口服對被感染流感的人顯著降低了家庭成員感染病毒的可能性。
Also Read: Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections.
此外，還了解到：羅氏公司的兩種皮下注射劑獲得連續的FDA批准。
Xofluza was well tolerated, and no new safety signals were identified.
Xofluza耐受性良好，未發現新的安全信號。
CENTERSTONE is the first global phase 3 study to show a transmission reduction benefit with an antiviral used to treat a respiratory viral illness.
CENTERSTONE是全球首個第3期研究，證明了一種用於治療呼吸道病毒性疾病的抗病毒藥物具有減少傳播的益處。
This new data may add to the benefits of Xofluza, which is currently approved for treating symptoms and preventing infection following virus exposure.
這些新數據可能進一步證明Xofluza的益處，目前該藥物已獲得用於治療症狀和預防病毒暴露的批准。
"Building on Xofluza's established efficacy in treating and preventing influenza after exposure, this new evidence of transmission reduction represents an important advance that could help improve health outcomes at an individual and community level," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. "We look forward to discussing these data with regulatory authorities and public health organizations for influenza pandemic preparedness to bring these benefits to patients."
羅氏首席醫學官兼全球產品開發負責人Levi Garraway萬.D., Ph.D.表示:"在治療和預防病毒暴露後，Xofluza已經證實的有效性的基礎上，這些新的傳播減少的證據代表了重要進展，可以幫助改善個體和社區層面的健康結果。" "我們期待與監管機構和公共衛生組織討論這些數據，以便爲流感大流行做好準備，並將這些益處帶給患者。"
Influenza is one of the most common yet serious infectious diseases. Every year, seasonal influenza infects an estimated one billion people and causes millions of hospitalizations and up to 650,000 deaths globally.
流感是最常見但嚴重的傳染病之一。每年，季節性流感感染約10億人，導致數百萬次住院和全球高達650,000人死亡。
Federal funds from the US Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority have partially supported the CENTERSTONE study.
美國衛生與公衆服務部、戰略準備與應對管理局以及生物醫藥高級研究與開發局部分支持了CENTERSTONE研究。
- FactSet Research Q4 Earnings: Revenue And Profit Beat, Adds 188 New Clients, Margin Boost And More.
- FactSet研究四季度收入和利潤超預期，增加了188個新客戶，提高了利潤率等。
譯文內容由第三人軟體翻譯。